Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

Subject

Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.-, Lancet (London, England), cilt.397, ss.592-604, 2021

URI

http://hdl.handle.net/20.500.12645/28448

Collections